Development of the composition and justification of the technology of biodegradable films with etoricoxib

DOI: https://doi.org/10.29296/25419218-2024-05-03
Issue: 
5
Year: 
2024

Y.V. Miroshnichenko, Y.Y. Zhidkova, E.A. Klimkina, O.A. Vatanskaya, A.A. Kovaleva
Federal State Budgetary Military Educational Institution of Higher Education “Military Medical Academy named after S.M.Kirov”
of the Ministry of Defense of the Russian Federation, Academician Lebedev str., 6, Saint-Petersburg, 194044, Russian Federation

Introduction. One of the current directions of pharmaceutical development is the creation of new drugs with anti-inflammatory and analgesic activity. Among the promising dosage forms are biodegradable films, which have a number of advantages over traditionally used forms. The use of biodegradable films containing nonsteroidal anti-inflammatory drugs as active ingredients prevents a number of side effects characteristic of oral dosage forms containing these drugs that enter directly into the gastrointestinal tract. Objective: development of the optimal composition and substantiation of the technology of biodegradable films containing etoricoxib as an active ingredient, which has anti-inflammatory and analgesic activity. Material and methods. The following pharmaceutical substances and excipients approved in the territory of the Russian Federation were used in the development of the composition of biodegradable films: etoricoxib (manufacturer Alembic Pharmaceuticals Ltd, India, serial number 2102010991), gelatin (PA.2.1.0099.18), sodium carmellose (PA.2.1.0377), dextrose (PA.2.1.0092.18), cocoa powder (SIS 108-214), citric acid (PA.2.1.0024.15), peppermint oil (PA.2.4.0001.18), glycerol (PA.2.2.0006.15), miramistin (PA 42-3498-98), sodium chloride (PA.2.2.0014), purified water (PA.2.2.0020). The rationale for the choice of a carrier matrix was carried out by studying film-forming polymers with the addition of pharmacologically active and auxiliary substances permitted in the territory of the Russian Federation. The quality indicators of polymer bases were evaluated by organoleptic and pharmaceutical-technological characteristics. To determine the dosing uniformity index, a VM-153M laboratory electronic scale (manufacturer LLC OKB Vesta, Saint-Petersburg, Russia) was used. The quality of the polymer bases was evaluated by organoleptic parameters and pharmaceutical and technological characteristics. Statistical analysis methods were used to substantiate the reliability of the results. Results. As a result of the theoretical and experimental studies carried out, the choice of the active substance – a nonsteroidal anti–inflammatory agent of selective action etoricoxib was made and its optimal dosage of 60 mg was justified, providing significant relief of pain and improvement of the condition of patients suffering from osteoarthritis. The optimal composition of a biodegradable film containing 2.14% etoricoxib, 7.14% gelatin, 10.00% glycerol, 2.14% miramistin, 4.29% dextrose, 2.86% cocoa powder and 71.42% purified water has been developed. An optimal technology for the production of biodegradable films has been developed and justified, which is based on the method of casting films in the form of a suspension due to the availability of the technological process. Conclusion. As a result of the conducted research, the optimal composition and technology of biodegradable films with etoricoxib based on gelatin have been theoretically and experimentally substantiated and developed. It has been established that the developed composition has satisfactory organoleptic properties and pharmaceutical and technological characteristics.
Keywords: 
biodegradable film
composition development
technology development
etoricoxib.
References: 
  1. Ножкина Н.Н., Синицкий А.И., Симонян Е.В. Оценка антиоксидантного действия биорастворимой лекарственной пленкой с кислотой янтарной и цетилпиридиния хлоридом. Медицинский вестник Башкортостана. 2016; 11 (5): 93–5. [Nozhkina N.N., Sinitskiy A.I., Simonyan E.V. Evaluation of antioxidant action of biodegradable medicinal films containing succinic acid and cetylpyridinium chloride. Bashkortostan Medical J. 2016; 11 (5): 93–5 (in Russian)]
  2. Плетнева И.В., Петрухина Д.А., Покровская Ю.С. Разработка технологии и исследование биорастворимых пленок лекарственных противовоспалительного действия. Медико-фармацевтический журнал «Пульс». 2021; 23 (2): 80–6. DOI: http://dx.doi.org/10.26787/nydha-2686-6838-2021-23-2-80-86. [Pletneva I.V., Petrukhina D.A., Pokrovskaya Y.S. Development of technology and research of water-soluble films of medicinal anti-inflammatory action. Medical & pharmaceutical journal «Pulse». 2021; 23 (2): 80–6. DOI: http://dx.doi.org/10.26787/nydha-2686-6838-2021-23-2-80-86 (in Russian)]
  3. Егорова А.С., Сапожникова М.Б., Обидченко Ю.А., Абрамович Р.А., Семкина О.А., Джавахян М.А. Быстрорастворимые пленки – инновационный способ доставки лекарственных средств. Вестник РУДН, серия Медицина. 2013; 3: 100–5. [Egorova A.S., Sapozhnikova M.B., Obidchenko Yu.A., Abramovich R.A., Semkina O.A., Dzhavakhyan M.A. Fast dissolving films – innovative method of drug delivery. RUDN J. of Medicine. 2013; 3: 100–5 (in Russian)]
  4. Кищенко В.М., Верниковский В.В., Привалов И.М., Шевченко А.М. Пленки в российской медицине и косметологии: история развития, классификация, технология. Фармация и фармакология. 2020; 8 (2): 124–32. DOI: 10.19163/2307-9266-2020-8-2-124-132. [Kishchenko V.M., Vernikovsky V.V., Privalov I.M., Shevchenko A.M. Films in russian medicine and cosmetology: development history, classification, technology. Pharmacy & pharmacology. 2020; 8 (2): 124–32. DOI: 10.19163/2307-9266-2020-8-2-124-132 (in Russian)]
  5. Жидкова Ю.Ю., Ковалева А.А. Современный ассортимент лекарственных препаратов в лекарственной форме «Пленки» в Российской Федерации и за рубежом. Актуальные вопросы развития российской фармации – Ильинские чтения. Сборник. 2022, 68–74. [Zhidkova U.U., Kovaleva A.A. The modern range of medicines in the medicinal form of «Films» in the Russian Federation and abroad. Actual issues of the development of Russian pharmacy – Ilyinsky readings. Sbornik. 2022, 68–74 (in Russian)]
  6. Каратеев А.Е., Насонов Е.Л., Погожева Е.Ю., Филатова Е.С., Амирджанова В.Н., Нестеренко В.А. Старый друг: 25 лет использования мелоксикама в России. Научно-практическая ревматология. 2021; 59 (3): 302–15. https://doi.org/10.47360/1995-4484-2021-302-315. [Karateev A.E., Nasonov E.L., Pogozheva E.Yu., Filatova E.S., Amirdzhanova V.N., Nesterenko V.A. An old friend: 25 years of meloxicam use in Russia. Rheumatology Science and Practice. 2021; 59 (3): 302–15. https://doi.org/10.47360/1995-4484-2021-302-315 (in Russian)]
  7. Каратеев АЕ. Терапевтический потенциал эторикоксиба в клинической практике. Современная ревматология. 2020; 14 (1): 108–17. DOI: 10.14412/1996-7012-2020-1-108-117. [Karateev A.E. The therapeutic potential of etoricoxib in clinical practice. Modern Rheumatology J. 2020; 14 (1): 108–17. DOI: 10.14412/1996-7012-2020-1-108-117 (in Russian)]
  8. Каратеев А.Е. Целекоксиб, эторикоксиб, мелоксикам и нимесулид: достоинства и недостатки. Эффективная фармакотерапия. Ревматология. Травматология. Ортопедия. 2011; 1: 28–36. [Karateev A.E. Celecoxib, etoricoxib, meloxicam and nimesulide: advantages and disadvantages. Effective pharmacotherapy. Rheumatology, Traumatology & Orthopaedics. 2011; 1: 28–36 (in Russian)]
  9. . Дыдыкина И.С., Коваленко П.С. Основные аспекты профилактики и лечения НПВП-гастропатии в свете новой идеологии современной медицины. Терапия. 2019; 1: 182–92. DOI: https://dx.doi.org/10.18565/therapy.2019.1.182-192. [Dydykina I.S., Kovalenko P.S. The mail aspects of the prevention and treatment of NSAID gastropathy in the light of the new ideology of modern medicine. Therapy. 2019; 1: 182–92. DOI: https://dx.doi.org/10.18565/therapy.2019.1.182-192 (in Russian)]
  10. . Леонова М.В. Новые лекарственные формы и системы доставки лекарственных средств: особенности пероральных лекарственных форм. Часть 1. Лечебное дело. 2009; 2: 21–31. [Leonova M.V. New medicines and drug delivery systems: the peculiarities of oral forms. Part 1. General Medicine. 2009; 2: 21–31 (in Russian)]
  11. Краснюк И.И., Овсянникова Л.В., Степанова О.И., Беляцкая А.В. [и др.] Применение твердых дисперсий с нестероидными противовоспалительными средствами в фармации. Разработка и регистрация лекарственных средств. 2016; 2 (15): 40–4. [Krasnuk I.I. (junior), Ovsyannikova L.V., Stepanova O.I., Belyatskaya A.V. et al. Application of solid dispersions with nonsteroidal anti-inflammatory drugs in pharmacy. Drug development & registration. 2016; 2 (15): 40–4 (in Russian)]
  12. Заводовский Б.В., Сивордова Л.Е., Полякова Ю.В., Ахвердян Ю.Р. [и др.] Сравнительная эффективность и безопасность эторикоксиба и мелоксикама в лечении больных гонартрозом. Терапевтический архив. 2016; 12: 78–81. DOI: 10.17116/terarkh2016881278-81. [Zavodovsky B.V., Sivordova L.E., Polyakova Yu.V., Akhverdyan Yu.R. et al. The efficacy and safety of etoricoxib versus meloxicam in the treatment of patients with gonarthrosis. Terapevticheskii Arkhiv (Ter. Arkh.). 2016; 12: 78–81. DOI: 10.17116/terarkh2016881278-81 (in Russian)]
  13. Камчатнов П.Р., Ханмурзаева С.Б., Чугунов А.В. Возможность применения препарата Костарокс (эторикоксиб) у пациентов с поясничной болью. Нервные болезни. 2020; 4: 41–7. DOI: 10.24412/2226-0757-2020-12242. [Kamchatnov P.R., Khanmurzaeva S.B., and Chugunov A.V. Opportunities of Kostarox (Etoricoxib) therapy in patients with low back pain. Nervous diseases. 2020; 4: 41–7 (in Russian)]
  14. Мустафин Р.И., Гарипова В.Р., Селмин Ф., Целурзо Ф. Диспергируемые в ротовой полости лекарственные формы (обзор). Разработка и регистрация лекарственных средств. 2015; 4 (13): 34–8. [Moustafine R.I., Garipova V.R., Selmin F., Cilurzo F. Orodispersible dosage forms (review). Drug development & registration. 2015; 4 (13): 34–8 (in Russian)]
  15. Тимергалиева В.Р., Хуснутдинов Р.Р., Мусина Р.Р., Елизарова Е.С., Алсынбаев Р.Р., Насибуллин Ш.Ф., Мустафин Р.И. Разработка диспергируемых в полости рта таблеток ибупрофена на основе полимер-лекарственного комплекса. Разработка и регистрация лекарственных средств. 2022; 11 (3): 113–20. https://doi.org/10.33380/2305-2066-2022-11-3-113-120. [Timergalieva V.R., Khusnutdinov R.R., Musina R.R., Elizarova E.S., Alsynbaev R.R., Nasibullin Sh.F., Moustafine R.I. Development of Orodispersible Ibuprofen Tablets Based on a Polymer-drug Complex. Drug development & registration. 2022; 11 (3): 113–20. https://doi.org/10.33380/2305-2066-2022-11-3-113-120 (in Russian)]